Biology
Molecular Basis of Cystic Fibrosis and CFTR Modulator Therapies
Quick fact
The most common CF mutation, ΔF508, removes a single amino acid (phenylalanine) from the CFTR protein, yet it causes the protein to fold incorrectly, be degraded, and never reach the cell surface—over 70% of people with CF carry this mutation.
Why this is interesting
You've probably heard of cystic fibrosis, but what if the real villain is a single microscopic protein that works like a faulty bouncer at a club? How can a tiny mutation cause such devastating effects?
Read the full explanation
Understanding Molecular Basis of Cystic Fibrosis and CFTR Modulator Therapies
Imagine a building with a special door that lets salt and water in and out. In our cells, this 'door' is a protein called CFTR (Cystic Fibrosis Transmembrane Conductance Regulator), which acts as a chloride channel. Normally, it sits on the surface of cells lining our lungs, pancreas, and sweat glands, opening and closing to let chloride ions out. Water follows chloride, keeping the mucus lining thin and slippery. In cystic fibrosis, genetic mutations disrupt this channel. Some mutations cause the protein to be made incorrectly (folding defect), some stop it from opening properly, and others cut it short entirely. This leads to thick, sticky mucus that clogs organs, causing breathing problems, infections, and digestive issues.
A deeper explanation
CFTR is a large protein with multiple domains, including an ATP-binding domain and a regulatory region. Its function depends on proper synthesis, folding, trafficking to the plasma membrane, and regulated opening (gating). Mutations can affect any step. The ΔF508 mutation (a deletion of phenylalanine at position 508) causes misfolding, leading to ER-associated degradation and premature removal. Other mutations (e.g., G551D) affect gating, meaning the channel reaches the surface but doesn't open properly. CFTR modulator therapies are designed to correct these defects: correctors (like lumacaftor) act as 'chaperones' to help fold the protein correctly, allowing it to reach the surface; potentiators (like ivacaftor) help the channel open more often. There are also amplifiers that increase protein production and read-through agents for premature stop codons. By using combinations of these drugs, we can target different molecular defects, explaining why therapy is tailored to a patient's specific mutation class—this is precision medicine in action.